NYC Announced 1:8 Common Stock Reverse Stock Split

New York City REIT, Inc. (NYSE: NYC) ("NYC" or the "Company") announced today that it intends to expand the scope of the assets and businesses the Company may own and operate.

New York City REIT, Inc. (NYSE:NYC) (“NYC” or the “Company”) announced today that it intends to expand the scope of the assets and businesses the Company may own and operate. By investing in other asset types, the Company may generate income that does not otherwise constitute income that qualifies for purposes of qualifying as a Real Estate Investment Trust or (“REIT”). As a result, the Company expects to change its REIT election and become a taxable C corporation. The election if and when made, would be effective as of January 1, 2023.

“We are excited to expand the scope of NYC beyond Manhattan real estate, which we believe will allow us to diversify our revenue streams and pursue opportunities that may not have been previously available to us,” said Michael Weil, CEO of NYC. “While we continue to believe in the long-term necessity of New York City real estate, the pace of recovery of the office segment since the COVID outbreak remains challenged. Despite the resilient performance of our portfolio over the last two years, portfolio growth has been incremental, and we believe that we will be able to generate greater growth and profitability by evolving NYC’s business strategy.”

Additionally, NYC announced that its board approved a 1-for-8 reverse stock split pursuant to which each outstanding share of common stock will be converted into 0.125 shares of common stock (no fractional shares will be issued). The reverse stock split is expected to be effective at 5:00p.m. eastern time on January 11, 2023. Further, subject to executing necessary documents and board approval, the Company intends to launch a rights offering to raise additional capital from existing stockholders.

Strategic and Financial Rationale

Diversification May Offset Prolonged New York City Office Rebound: The pace of recovery in the New York City office market from the COVID-19 pandemic continues to be challenged as leasing and occupancy trends for the broader market have slowed, leading political, community, and business leaders to propose repositioning plans for New York City office assets.
Additional Capital Raising Opportunities: NYC can potentially raise additional capital from existing stockholders and, in the future, from a broader base of new investors which may not have been previously available to NYC, who seek companies with greater asset and business diversification and deploy potential proceeds in income generating ventures.
External Growth Opportunities: NYC believes that the Company may achieve external growth by expanding the scope of the assets and businesses the Company may own and operate.
Increased Diversification: By expanding the nature and type of assets NYC seeks to own and acquire, NYC can potentially reduce single asset class exposure and increase corporate flexibility and income generated.
Potential to Use Net Operating Loss Carryforwards: Even if NYC terminates it status as a REIT, the Company may be able to use existing or future net operating loss carryforwards to limit the tax on any future income.

Total
0
Shares
Related Posts
Read More

Enjoy, Eni’s Car Sharing Service, is Going Electric in Bologna

Enjoy, Eni's car sharing service, is going electric in Bologna, with the introduction of the battery swapping equipped city cars XEV YOYO to its fleet. The news was announced today at Palazzo Gnudi in the presence of Valentina Orioli, Councillor for New Mobility of the Municipality of Bologna, who spoke together with Giuseppe Ricci, Eni Energy Evolution Chief Operating Officer.

E

Read More

Regeneron Pharmaceuticals Announced Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH 2022

- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new and updated data from a Phase 1 and pivotal Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

REGN